EP 1011608 A2 20000628 - COMPOSITION AND METHOD FOR PREVENTION AND TREATMENT OF CARDIOPULMONARY AND RENAL FAILURE OR DAMAGE ASSOCIATED WITH ISCHEMIA, ENDOTOXIN RELEASE, ARDS OR BROUGHT ABOUT BY ADMINISTRATION OF CERTAIN DRUGS
Title (en)
COMPOSITION AND METHOD FOR PREVENTION AND TREATMENT OF CARDIOPULMONARY AND RENAL FAILURE OR DAMAGE ASSOCIATED WITH ISCHEMIA, ENDOTOXIN RELEASE, ARDS OR BROUGHT ABOUT BY ADMINISTRATION OF CERTAIN DRUGS
Title (de)
ZUSAMMENSETZUNG UND METHODE ZUR PRÄVENTION UND BEHANDLUNG VON HERZLUNGEN-UND NIERENVERSAGEN ODER SCHÄDEN DIE IM ZUSAMMENHANG STEHEN MIT ISCHÄMIE, ENDOTOXIN FREISETZUNG, ARDS ODER HERVORGERUFEN WERDEN DURCH DIE GABE BESTIMMTER MEDIKAMENTE
Title (fr)
COMPOSITION ET PROCEDE POUR LA PREVENTION ET LE TRAITEMENT DE L'INSUFFISANCE CARDIO-PULMONAIRE ET RENALE, OU DES LESIONS CONSECUTIVES A L'ISCHEMIE, LA LIBERATION D'ENDOTOXINES, L'EMPHYSEME PULMONAIRE OU A L'ADMINISTRATION DE CERTAINS MEDICAMENTS
Publication
Application
Priority
- US 9912775 W 19990608
- US 8850198 P 19980608
- US 9397298 A 19980609
- US 8865798 P 19980609
Abstract (en)
[origin: WO9963938A2] A pharmaceutical composition comprises an agent such as an adenosine A2a agonist agent and/or nucleic acid comprising an oligonucleotide(oligo) that is anti-sense to an adenosine A1, A2a, A2b or A3 receptor gene, mRNA, flanking regions or regions bridging the intro/exon borders, which oligos are effective to prevent, alleviate or inhibit adenosine-mediated cardiac, pulmonary and/or renal functional difficulties, damage or failure, such as those observed in diseases and conditions such as ARDS, hypoxia, etc. or associated with the administration of therapeutic and diagnostic agents such as adenosine cysplatin, metal ion-containing agents, etc., mixtures thereof, and optionally a surfactant, a carrier and other therapeutic and diagnostic agents and other formulation components. The composition is provided in the form of various formulations that are, for example, effective for preventing or alleviating bronchoconstriction, allergy and/or inflammation associated with ARDS, RDS, etc., deleterious side effects observed upon treatment of SVT patients, upon administration of cardiac stress tests or imaging tests, etc.
IPC 1-7
IPC 8 full level
A61K 31/00 (2006.01); A61K 45/06 (2006.01); C12N 15/11 (2006.01); C12N 15/113 (2010.01); A61K 38/00 (2006.01)
CPC (source: EP)
A61K 31/00 (2013.01); A61K 31/7076 (2013.01); A61K 45/06 (2013.01); C12N 15/1138 (2013.01); A61K 38/00 (2013.01); C12N 2310/315 (2013.01); C12N 2310/33 (2013.01); C12N 2310/3341 (2013.01)
Designated contracting state (EPC)
AT BE CH DE DK ES FI FR GB GR IE IT LI NL PT SE
DOCDB simple family (publication)
WO 9963938 A2 19991216; WO 9963938 A3 20000127; WO 9963938 A9 20000302; AU 4675699 A 19991230; CA 2316994 A1 19991216; EP 1011608 A2 20000628; EP 1011608 A4 20020515
DOCDB simple family (application)
US 9912775 W 19990608; AU 4675699 A 19990608; CA 2316994 A 19990608; EP 99930160 A 19990608